Wed Dec 15,2011 1:39pm
Discovery Laboratories, Inc.
DSCO.O
$0.19
+0.02+10.74%
Discovery Labs, commented, "We are pleased with the guidance received and outcomes obtained from our interaction with the FDA. This guidance provides a viable option for Surfaxin and meaningfully supports advancing our pipeline initiatives to potentially address a broad range of respiratory diseases such as RDS, Acute Respiratory Failure, Acute Lung Injury and Cystic Fibrosis. We look forward to continued productive dialogue with the FDA.
"Our most advanced programs from our KL4 surfactant pipeline, Surfaxin, Surfaxin LS(TM) and Aerosurf(R), have the potential to greatly improve the management of RDS and to redefine the RDS market. Our top priority is to secure strategic alliance partners and access capital to advance our pipeline and build shareholder value. As we move forward, we will take into account further interaction with the FDA and make strategic assessment, together with existing and potential new partners to determine the appropriate level and timing of Surfaxin investment and to maximize the value of our KL4 pipeline for RDS."
Accordingly, Discovery Labs initiated a series of side-by-side studies employing both the preterm lamb model of RDS and the BAT and believes that the correlated results demonstrate comparability and support approval of Surfaxin.
Our goal as a company is to bring life changes into the medical community,and to bring profitabilty back to our shareholders.
Recent WINT News
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 08:24:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 08:20:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 08:13:06 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2024 08:11:20 PM
- Windtree Announces New Additions and Changes to Its Board of Directors • GlobeNewswire Inc. • 08/14/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/29/2024 12:33:56 PM
- Form RW - Registration Withdrawal Request • Edgar (US Regulatory) • 07/25/2024 08:07:25 PM
- Windtree Therapeutics Provides Update on Istaroxime Clinical Development and Upcoming Clinical Trial Data • GlobeNewswire Inc. • 07/25/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/24/2024 09:28:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/24/2024 09:27:47 PM
- Windtree Therapeutics Announces Closing of Financing Through a Private Placement of Series C Preferred Stock • GlobeNewswire Inc. • 07/22/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/22/2024 01:25:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/10/2024 08:53:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 08:59:51 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 05/09/2024 12:41:34 PM
- Windtree Therapeutics Regains Compliance with Nasdaq • GlobeNewswire Inc. • 05/07/2024 12:00:00 PM
- Windtree Therapeutics Announces Reverse Stock Split • GlobeNewswire Inc. • 04/18/2024 12:00:00 PM
- Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates • GlobeNewswire Inc. • 04/17/2024 12:00:00 PM
- Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge Financing • GlobeNewswire Inc. • 04/08/2024 08:48:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 10:07:43 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/14/2024 10:23:27 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:30:23 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:15:54 AM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/12/2024 09:40:42 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/01/2024 10:26:23 PM
HealthLynked Corp. Announces Second Quarter and First Half 2024 Results: Continued Cost Reductions Set the Stage for Strategic Shift to App-Based Technology Services • HLYK • Aug 16, 2024 8:00 AM
PickleJar Announces Official Name Change and New Ticker Symbol • NREG • Aug 15, 2024 2:23 PM
VAYK's Q2 Profit Added to Accumulated Net Profit of Over $2.2 Million In 18 Months • VAYK • Aug 15, 2024 9:07 AM
Swifty Global Reports Strong Q2 Performance and Prepares for Major Exchange Uplisting • DRCR • Aug 15, 2024 9:04 AM
Mayback's Global Entertainment Signs Global Distribution Agreement with Children's Media Studio • AHRO • Aug 15, 2024 8:45 AM
POET Technologies Reports Second Quarter 2024 Financial Results • POET • Aug 15, 2024 8:04 AM